PMID- 29266395
OWN - NLM
STAT- MEDLINE
DCOM- 20180905
LR  - 20181202
IS  - 1600-0609 (Electronic)
IS  - 0902-4441 (Linking)
VI  - 100
IP  - 4
DP  - 2018 Apr
TI  - Arsenic trioxide at conventional dosage does not aggravate hemorrhage in the 
      first-line treatment of adult acute promyelocytic leukemia.
PG  - 344-350
LID - 10.1111/ejh.13018 [doi]
AB  - OBJECTIVES: The arsenic trioxide (ATO) plus all-trans retinoic acid (ATRA) 
      therapy has demonstrated a tremendous success in the first-line treatment of 
      acute promyelocytic leukemia (APL). Actually, early death (ED) is currently 
      thought as a major challenge in APL. ATO has been reported to inhibit platelet 
      function in vitro, and whether it increases the ED rate by exacerbating the 
      hemorrhagic symptoms remains to be investigated. METHODS: Effects of ATO on 
      platelet aggregation and adhesion were evaluated in vitro and in thirty-two 
      complete remission (CR) and four newly diagnosed APL patients. Furthermore, 
      concentrations of plasma total arsenic were monitored in APL patients via ICP-MS. 
      RESULTS: The inhibition of platelet function, either aggregation or adhesion, did 
      occur in vitro when the concentration of ATO reached 2 mumol/L. However, in CR APL 
      patients receiving ATO with normal platelet count, the platelets responded 
      normally when being activated and so did those in the newly diagnosed patients 
      with thrombocytopenia. Our data further showed that the conventional dosage of 
      ATO reached a plasma concentration substantially below the required concentration 
      to inhibit platelets. CONCLUSIONS: In the first-line treatment of APL, the use of 
      ATO is safe and effective and does not compromise the hemostatic potential that 
      may eventually increase ED rate.
CI  - (c) 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Cui, Wen
AU  - Cui W
AD  - Shanghai Institute of Hematology, State Key Laboratory for Medical Genomics and 
      Department of Hematology, Collaborative Innovation Center of Systems Biomedicine, 
      Pole Sino-Francais des Sciences du Vivant et Genomique, Rui Jin Hospital 
      Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
AD  - Department of Clinical Laboratory, Shanghai Municipal Hospital of Traditional 
      Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 
      China.
FAU - Wang, Jin
AU  - Wang J
AD  - Shanghai Institute of Hematology, State Key Laboratory for Medical Genomics and 
      Department of Hematology, Collaborative Innovation Center of Systems Biomedicine, 
      Pole Sino-Francais des Sciences du Vivant et Genomique, Rui Jin Hospital 
      Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
FAU - Nie, Rui-Min
AU  - Nie RM
AD  - Shanghai Institute of Hematology, State Key Laboratory for Medical Genomics and 
      Department of Hematology, Collaborative Innovation Center of Systems Biomedicine, 
      Pole Sino-Francais des Sciences du Vivant et Genomique, Rui Jin Hospital 
      Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
FAU - Zhao, Ling-Ling
AU  - Zhao LL
AD  - Department of Clinical Laboratory, Shanghai Xuhui Central Hospital, Shanghai, 
      China.
FAU - Gao, Meng-Qing
AU  - Gao MQ
AD  - Shanghai Institute of Hematology, State Key Laboratory for Medical Genomics and 
      Department of Hematology, Collaborative Innovation Center of Systems Biomedicine, 
      Pole Sino-Francais des Sciences du Vivant et Genomique, Rui Jin Hospital 
      Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
FAU - Zhu, Hong-Ming
AU  - Zhu HM
AD  - Shanghai Institute of Hematology, State Key Laboratory for Medical Genomics and 
      Department of Hematology, Collaborative Innovation Center of Systems Biomedicine, 
      Pole Sino-Francais des Sciences du Vivant et Genomique, Rui Jin Hospital 
      Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
FAU - Chen, Li
AU  - Chen L
AD  - Shanghai Institute of Hematology, State Key Laboratory for Medical Genomics and 
      Department of Hematology, Collaborative Innovation Center of Systems Biomedicine, 
      Pole Sino-Francais des Sciences du Vivant et Genomique, Rui Jin Hospital 
      Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
FAU - Hu, Jiong
AU  - Hu J
AD  - Shanghai Institute of Hematology, State Key Laboratory for Medical Genomics and 
      Department of Hematology, Collaborative Innovation Center of Systems Biomedicine, 
      Pole Sino-Francais des Sciences du Vivant et Genomique, Rui Jin Hospital 
      Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
FAU - Li, Jun-Min
AU  - Li JM
AD  - Shanghai Institute of Hematology, State Key Laboratory for Medical Genomics and 
      Department of Hematology, Collaborative Innovation Center of Systems Biomedicine, 
      Pole Sino-Francais des Sciences du Vivant et Genomique, Rui Jin Hospital 
      Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
FAU - Shen, Zhi-Xiang
AU  - Shen ZX
AD  - Shanghai Institute of Hematology, State Key Laboratory for Medical Genomics and 
      Department of Hematology, Collaborative Innovation Center of Systems Biomedicine, 
      Pole Sino-Francais des Sciences du Vivant et Genomique, Rui Jin Hospital 
      Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
FAU - Wang, Zhen-Yi
AU  - Wang ZY
AD  - Shanghai Institute of Hematology, State Key Laboratory for Medical Genomics and 
      Department of Hematology, Collaborative Innovation Center of Systems Biomedicine, 
      Pole Sino-Francais des Sciences du Vivant et Genomique, Rui Jin Hospital 
      Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
FAU - Chen, Sai-Juan
AU  - Chen SJ
AD  - Shanghai Institute of Hematology, State Key Laboratory for Medical Genomics and 
      Department of Hematology, Collaborative Innovation Center of Systems Biomedicine, 
      Pole Sino-Francais des Sciences du Vivant et Genomique, Rui Jin Hospital 
      Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
FAU - Chen, Zhu
AU  - Chen Z
AD  - Shanghai Institute of Hematology, State Key Laboratory for Medical Genomics and 
      Department of Hematology, Collaborative Innovation Center of Systems Biomedicine, 
      Pole Sino-Francais des Sciences du Vivant et Genomique, Rui Jin Hospital 
      Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
FAU - Wang, Kan-Kan
AU  - Wang KK
AD  - Shanghai Institute of Hematology, State Key Laboratory for Medical Genomics and 
      Department of Hematology, Collaborative Innovation Center of Systems Biomedicine, 
      Pole Sino-Francais des Sciences du Vivant et Genomique, Rui Jin Hospital 
      Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
FAU - Xi, Xiao-Dong
AU  - Xi XD
AD  - Shanghai Institute of Hematology, State Key Laboratory for Medical Genomics and 
      Department of Hematology, Collaborative Innovation Center of Systems Biomedicine, 
      Pole Sino-Francais des Sciences du Vivant et Genomique, Rui Jin Hospital 
      Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
AD  - Collaborative Innovation Center of Hematology, Shanghai, China.
FAU - Mi, Jian-Qing
AU  - Mi JQ
AUID- ORCID: 0000-0002-0769-5437
AD  - Shanghai Institute of Hematology, State Key Laboratory for Medical Genomics and 
      Department of Hematology, Collaborative Innovation Center of Systems Biomedicine, 
      Pole Sino-Francais des Sciences du Vivant et Genomique, Rui Jin Hospital 
      Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
LA  - eng
PT  - Journal Article
DEP - 20180209
PL  - England
TA  - Eur J Haematol
JT  - European journal of haematology
JID - 8703985
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Arsenicals)
RN  - 0 (Oxides)
RN  - S7V92P67HO (Arsenic Trioxide)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antineoplastic Agents/*administration & dosage/adverse effects/pharmacokinetics
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use
MH  - Arsenic Trioxide
MH  - Arsenicals/*administration & dosage/adverse effects/pharmacokinetics
MH  - Blood Coagulation/drug effects
MH  - Female
MH  - Hemorrhage/*etiology/mortality
MH  - Humans
MH  - Leukemia, Promyelocytic, Acute/blood/*complications/*drug therapy
MH  - Maintenance Chemotherapy
MH  - Male
MH  - Middle Aged
MH  - Oxides/*administration & dosage/adverse effects/pharmacokinetics
MH  - Platelet Adhesiveness/drug effects
MH  - Platelet Aggregation/drug effects
MH  - Platelet Function Tests
MH  - Remission Induction
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - acute promyelocytic leukemia
OT  - arsenic trioxide
OT  - early death
OT  - platelet function
EDAT- 2017/12/22 06:00
MHDA- 2018/09/06 06:00
CRDT- 2017/12/22 06:00
PHST- 2017/11/28 00:00 [accepted]
PHST- 2017/12/22 06:00 [pubmed]
PHST- 2018/09/06 06:00 [medline]
PHST- 2017/12/22 06:00 [entrez]
AID - 10.1111/ejh.13018 [doi]
PST - ppublish
SO  - Eur J Haematol. 2018 Apr;100(4):344-350. doi: 10.1111/ejh.13018. Epub 2018 Feb 9.